(AP) -- More than 1,600 people who filed lawsuits claiming that their health was ruined by dust and smoke from the collapsed World Trade Center must decide by Jan. 2 whether to keep fighting in court, or drop the litigation ...
Dec 26, 2011
2
0
Personalization, something made especially for you, can make everything better, from the clothes you wear to the car you drive. Now, the type of medical treatment you receive can also be personalized.
Oct 1, 2021
0
0
A team of scientists at the Keck School of Medicine of USC is looking to some deep sea dwellers to create a better way to develop cancer-fighting therapies. Harnessing the power of the enzymes that give these marine animals ...
Jan 9, 2018
0
82
A newly published reanalysis of raw data from a study widely used by chemical assessment agencies to set hazard assessments for formaldehyde shows no link between formaldehyde exposure and leukemia. The peer-reviewed paper ...
May 2, 2017
0
0
An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) - a poor-prognosis group with few options - report investigators ...
Dec 8, 2014
0
0
In geriatric medicine, the adage that age is just a number holds true. New research from Wake Forest Baptist Medical Center uses a simple assessment tool to determine how well older adults diagnosed with acute myelogenous ...
Oct 26, 2011
0
0
Researchers at Moffitt Cancer Center and colleagues have discovered that changes in the physical characteristics of the effector memory regulatory T cell can predict the progression risk of myelodysplastic syndromes (MDS) ...
Sep 13, 2012
0
0
A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival ...
Apr 17, 2013
0
0
Scientists at Fox Chase Cancer Center have uncovered more details about how defects in components of the machinery that makes new proteins can lead to blood and other cancers. The findings, which will be presented at the ...
Apr 2, 2012
0
0
The University of Texas MD Anderson Cancer Center and Amgen have announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a "bridge" ...
Jan 13, 2015
0
5
